IP Library Granted Patent US 7,005,502
Granted Patent B1
US 7,005,502 · App. 09/424,498 · Granted Feb 28, 2006

Pharmaceutical preparation comprising vWF propeptide

Assignee: Baxter Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,005,502
App. No.
09/424,498
Granted
Feb 28, 2006
Kind
B1
Abstract

Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWf propeptide as well as a method for producing such a prepartion.

Claims (5)

1. A pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising at least 10 nM von Willebrand Factor (vWF) propeptide and a hemostasis protein, wherein said preparation has been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.

2. A preparation as set forth in claim 1 , wherein said hemostasis protein is a blood factor.

3. A preparation as set forth in claim 2 , wherein said blood factor is selected from the group consisting of mature vWF, factor VIII, activated blood coagulation factors, and blood factors with factor VIII inhibitor bypassing activity.

4. A pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising at least 10 nM von Willebrand Factor (vWF) propeptide and a phospholipid, wherein the preparation has been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.

5. A pharmaceutical preparation for treating blood coagulation disorders, said preparation comprising at least 10 nM von Willebrand Factor (vWF) propeptide and at least two components, wherein the components are selected from the group consisting of a blood factor, a platelet component, and a phospholipid, wherein said preparation has been treated for at least one of virus inactivation and virus removal so the preparation is suitable for therapeutic administration.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME, EXECUTION DATE, AND ADDRESS OF ASSIGNEE BAXALTA GMBH PREVIOUSLY RECORDED ON REEL 036366 FRAME 0445. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 4, 2016
From: BAXALTA INNOVATIONS GMBH
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 038345/0889 →
CHANGE OF NAME Recorded Mar 29, 2016
From: BAXTER INNOVATIONS GMBH
To: BAXALTA INNOVATIONS GMBH
Reel/Frame 038292/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INNOVATIONS GMBH
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036366/0445 →
CHANGE OF NAME Recorded Jan 6, 2009
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER INNOVATIONS GMBH
Reel/Frame 022071/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2000
From: SCHWARZ, HANS-PETER; VARADI, KATALIN; TURECEK, PETER; HEMKER, HENDRIK COENRAAD; BEGUIN, SUZETTE LUCETTE
To: BAXTER AKTIENGESELLSCHAFT
Reel/Frame 010605/0687 →
Priority Claims (1)
AT 917/97 · May 28, 1997 · national